MicroPort Scientific (HK:0853) has released an update.
MicroPort Scientific’s affiliate, Shanghai MicroPort Endovascular MedTech (EV MedTech), has reported a significant increase in financial performance for the first half of 2024, with a 26.63% jump in revenue and a 44.60% rise in profit compared to the same period in 2023. These results reflect only EV MedTech’s operations and are not indicative of MicroPort Scientific’s entire group performance. Investors are advised to exercise caution when trading company securities.
For further insights into HK:0853 stock, check out TipRanks’ Stock Analysis page.
